"The British Business Bank (BBB) has announced an £8 million investment into NRG Therapeutics Ltd., a pioneering neuroscience company developing novel therapies for severe neurodegenerative conditions, as part of a £50 million Series B funding round. The financing was led by SV Health Investors' Dementia Discovery Fund (DDF), with participation from M Ventures, Novartis Venture Fund, and Criteria Bio Ventures, alongside existing backers Omega Funds and Brandon Capital."
"NRG Therapeutics is advancing treatments for amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and Parkinson's disease by targeting mitochondrial dysfunction, a key driver of neurodegeneration. The company has developed a new class of small molecule mitochondrial permeability transition pore (mPTP) inhibitors, designed to protect mitochondria from toxic proteins linked to ALS/MND and Parkinson's, and preserve neurons in pre-clinical models. Its lead candidate, NRG5051, has shown profound neuroprotective effects and reduced neuroinflammation in pre-clinical studies."
The British Business Bank invested £8 million into NRG Therapeutics as part of a £50 million Series B led by SV Health Investors' Dementia Discovery Fund, with participation from M Ventures, Novartis Venture Fund, Criteria Bio Ventures, Omega Funds and Brandon Capital. NRG Therapeutics targets mitochondrial dysfunction in ALS/MND and Parkinson's through a novel class of small molecule mitochondrial permeability transition pore (mPTP) inhibitors designed to protect mitochondria from toxic proteins and preserve neurons. The lead candidate NRG5051 showed profound neuroprotective effects and reduced neuroinflammation in pre-clinical studies and has completed IND-enabling work. NRG5051 is expected to enter first-in-human trials in early 2026, and the Series B will fund clinical proof of concept in ALS/MND while collecting meaningful data in Parkinson's to support portfolio expansion.
Read at Business Matters
Unable to calculate read time
Collection
[
|
...
]